Intramuscular Ketamine Injection: Administration and Clinical Considerations

Overview of Intramuscular Ketamine Administration

Intramuscular (IM) ketamine injection delivers ketamine directly into muscle tissue, where it is absorbed into the bloodstream through the surrounding capillary network. This guide explains intramuscular ketamine injection administration and clinical considerations, including dosing, injection technique, and how the route compares to IV, oral, sublingual, and intranasal ketamine. While IV infusion remains the most studied route in psychiatric research, IM injection has decades of use in anesthesia and emergency medicine and is increasingly used by clinicians treating depression, PTSD, and other psychiatric conditions. It offers a practical middle ground between the precision of IV infusion and the convenience of oral or sublingual formulations, with higher bioavailability than oral routes, faster onset than sublingual administration, and less required equipment than IV infusion.

Pharmacokinetics of IM Ketamine

Absorption and Bioavailability

When ketamine is injected into muscle tissue, it is absorbed through the capillary network surrounding the muscle fibers. According to StatPearls, intramuscular ketamine has a bioavailability of approximately 93 percent, the second highest of any administration route after intravenous injection, which is 100 percent by definition. This is substantially higher than oral administration (17-24%), sublingual administration (25-30%), or intranasal administration (25-50%). Peak plasma concentrations following IM injection are typically reached within 5 to 15 minutes, compared to seconds for IV administration and 20 to 45 minutes for oral administration. Time to peak concentration depends on injection site, local muscle blood flow, injection volume, and the concentration of the ketamine solution.

Duration of Action

Psychoactive effects from IM ketamine typically last 45 to 90 minutes, somewhat shorter than a standard 40-minute IV infusion, where effects generally last 60 to 120 minutes from the start of the infusion, but longer than the effects of intranasal ketamine. The drug's pharmacological half-life remains approximately 2 to 3 hours regardless of the route used.

Onset Characteristics

IM ketamine tends to produce a more abrupt transition into the dissociative state than the gradual onset of a slow IV drip. Some patients report a sense of rapidly "going under" within 3 to 5 minutes of injection. This difference in onset affects both the patient experience and the monitoring approach a clinic needs to have in place.

Clinical Applications

Psychiatric Treatment

IM ketamine is used in psychiatric settings for many of the same indications as IV ketamine, primarily treatment-resistant depression. The National Institute of Mental Health (NIMH) describes depression as a common but serious mood disorder that affects how a person feels, thinks, and handles daily activities. IM ketamine is also used for post-traumatic stress disorder (PTSD), a condition that can develop after experiencing or witnessing a traumatic event, and for suicidal ideation. Clinicians who prefer IM administration often cite practical reasons: it requires less equipment than IV infusion, since there is no infusion pump, IV line, or tubing involved; it can be given by a wider range of clinical staff; it shortens treatment time, since the injection itself takes seconds rather than a 40-minute infusion; and it may be more practical in settings without infusion capabilities, such as psychiatric offices. That said, the evidence base specifically supporting IM ketamine for psychiatric indications is smaller than the evidence for IV ketamine. Most landmark clinical trials used IV administration, and the psychiatric literature on IM ketamine consists mainly of open-label studies, case series, and retrospective analyses. Our guide to ketamine treatment methods covers how the different routes compare in more detail.

Ketamine-Assisted Psychotherapy

IM injection is the preferred route in many ketamine-assisted psychotherapy (KAP) protocols. Practitioners in this modality often favor IM administration because its more defined onset and peak create a discrete therapeutic window that fits well with the psychotherapy framework. The shorter preparation time also leaves more of the session for psychological processing rather than medical setup. Typical KAP dosing for IM ketamine ranges from 0.5 to 1.0 mg/kg, though some protocols use higher doses, up to 3-4 mg/kg, to produce deeper dissociative or psychedelic-like experiences when clinically indicated.

Emergency Medicine and Anesthesia

IM ketamine has been a standard tool in emergency medicine and field anesthesia for decades. Its reliable absorption, preservation of airway reflexes, and hemodynamic stability make it valuable in settings where IV access is difficult to establish, including pediatric emergencies, prehospital care, and austere environments. In emergency psychiatric settings, IM ketamine is sometimes used for rapid management of acute agitation. The doses used for this purpose, typically 4-5 mg/kg for full sedation, are substantially higher than psychiatric treatment doses, reflecting an anesthetic rather than sub-anesthetic intent.

Dosing Protocols

Standard Psychiatric Dosing

IM ketamine dosing for psychiatric applications typically falls into four ranges:

• Low dose (0.25-0.5 mg/kg): Produces mild dissociative effects, often described as a relaxed, dreamlike state. Some clinicians use this range for patients who are new to ketamine or anxious about the experience.
• Standard dose (0.5-1.0 mg/kg): The most common range for depression and PTSD treatment, producing moderate dissociation and psychoactive effects comparable to a standard IV infusion.
• Higher dose (1.0-2.0 mg/kg): Produces more profound dissociation and is used in some KAP protocols where a deeper experiential state is therapeutically desired.
• Psychedelic dose (2.0-4.0 mg/kg): Used in specialized KAP settings to produce near-anesthetic, deeply dissociative experiences. This range requires experienced clinicians and close monitoring.

Injection Technique

IM ketamine is typically injected into the deltoid muscle in the upper arm or the vastus lateralis in the outer thigh. The gluteal muscles can also be used. Key technical considerations include using an appropriate needle gauge, typically 22-25 gauge, and length for the injection site; aspirating before injection to confirm the needle has not entered a blood vessel; injecting slowly and steadily to reduce discomfort; limiting the volume per injection site to generally no more than 3-4 mL to ensure reliable absorption; and splitting the injection between two sites when a dose requires a larger volume.

Patient Experience

Patients receiving IM ketamine commonly report a more sudden onset of dissociative effects compared with the gradual onset of IV infusion, a more intense peak experience due to the bolus-like delivery, a slightly shorter total duration of psychoactive effects, and possible injection site soreness lasting one to two days. Preparation and setup time is typically shorter for IM administration, which some patients prefer. The overall clinic visit may run one to two hours rather than the two to three hours typical of IV infusion sessions, though the post-treatment monitoring period remains similar.

Managing Adverse Effects

The most common adverse effects of IM ketamine, including nausea, dizziness, elevated blood pressure, and anxiety during onset, are similar to those seen with other routes. Nausea may be more common with IM than IV administration in some patients, possibly due to the more rapid absorption. Pre-treatment with ondansetron, an anti-nausea medication, is a common preventive strategy. Because the dose cannot be titrated in real time once injected, clinicians rely on accurate initial dosing and patient history to reduce the risk of adverse events. Starting new patients at lower doses and increasing gradually across sessions is standard practice.